ArticleBriefings in bioinformatics2025
Identifying potential miRNA-disease associations through an accurate matrix completion approach.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Computational Method Using Attribute-Aware Message Passing and Graph Convolutional Network for Potential miRNA-Disease Association Prediction.International journal of molecular sciences · 2026Article
- RLNSF-MDA: reliability-guided graph-regularized matrix factorization for immune-related miRNA-disease association prediction.Frontiers in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exploring latent microRNA (miRNA)-disease associations (MDAs) is vital for early screening and treatment. Compared with traditional experiments, computational methods enhance efficiency and lower costs in predicting MDAs. We trained the Accurate Matrix Completion for predicting potential MiRNA-Disease Associations (AMCMDA) model in this work, utilizing truncated nuclear norm minimization to improve the prediction accuracy. In AMCMDA, we begin by constructing a heterogeneous network incorporating both similarity and association information between miRNAs and diseases. Second, an optimization framework is designed to complete the effective approximation of the truncated nuclear norm to complement the missing values of the objective matrix. Finally, we solve this optimization problem via Alternating Direction Method of Multipliers and obtain the final prediction scores. After comparing the AMCMDA model with other models across three validation frameworks and three different datasets, we find that the AMCMDA model demonstrates robust and accurate performance. The model's excellent performance is also demonstrated by two categories of case studies on three diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.